These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 19063924

  • 1. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H.
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L, Verbeeck J, Van Kerckhove B, Berke JM, Koletzki D, Fanning G, Lenz O.
    Methods Mol Biol; 2013 Feb; 1030():105-17. PubMed ID: 23821263
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, Lenz O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
    Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G.
    J Biol Regul Homeost Agents; 2003 Oct; 17(2):198-204. PubMed ID: 14518724
    [Abstract] [Full Text] [Related]

  • 14. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I, Simmonds P.
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):692-7. PubMed ID: 19944069
    [Abstract] [Full Text] [Related]

  • 18. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, Cheng G.
    Antiviral Res; 2013 Nov 01; 100(2):439-45. PubMed ID: 24013001
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.
    Antivir Ther; 2015 Nov 01; 20(3):271-80. PubMed ID: 25222708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.